Moderna taps Baxter for vaccine fill/finish services

March 8, 2021

Baxter International will help fill vials and package about 60-90 million doses of Moderna's COVID-19 vaccine in 2021, as Moderna looks to boost vaccine supplies.

Baxter’s CMO arm, BioPharma Solutions, will provide fill/finish sterile manufacturing services and supply packaging for the vaccine from the company's sterile manufacturing facilities located in Bloomington, Indiana. The 600,000-square foot site has capabilities and expertise in parenteral delivery systems and clinical and commercial vaccine manufacturing.

Moderna, which expects to make 700 million to 1 billion doses of its vaccine this year, said in February that U.S. vaccine supplies were lagging because of “short-term delays” in the final stages of production at its contractor, Catalent. Moderna had announced the fill-finish deal with Catalent in June.  The Catalent facility is also located in Bloomington, Indiana. Back in April, J&J also signed a joint manufacturing deal with Catalent Biologics to help produce the 600-900 million doses of its coronavirus vaccine candidate it has promised by 2021.

Further details about the Baxter-Moderna deal were not made public.

Read the press release